The Estée Lauder Companies has taken a minority stake in luxury clinical skin care brand 111Skin as it sharpens its focus on science-backed beauty and treatment-led innovation.
Founded in 2012 by plastic and reconstructive surgeon Dr Yannis Alexandrides, 111Skin was originally developed to help accelerate patients’ healing following procedures.
The brand now sells more than 30 products, led by its Black Diamond and Reparative collections, and is distributed through luxury retail, ecommerce and high-end spa channels.
Its stockists include Harrods, Bluemercury, Nordstrom, Mandarin Oriental and Aman, while its direct-to-consumer business accounts for around 20 per cent of sales.
The Estée Lauder Companies president and chief executive Stéphane de La Faverie said skin care was entering “a new phase” shaped by the convergence of procedures, longevity and beauty.
He said consumers were increasingly looking for products that deliver “visible, treatment-inspired results”.
“111Skin exemplifies this shift, translating Dr Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skin care inspired by in-clinic treatments and built on clinical insight, next-generation actives, powerful formulas and proven efficacy,” he said.
In 2025, North America accounted for around 40 per cent of 111Skin’s sales, while the brand also has an established presence in the UK, China, Europe and Asia Pacific.
Following the investment, Alexandrides will remain actively involved in the business and will continue to lead 111Skin alongside its existing management team.
Alexandrides and co-founder Eva Alexandrides said: “We are thrilled to be partnering with The Estée Lauder Companies and to unlock an exciting new chapter for 111Skin.”
Click here to sign up to Retail Gazette‘s free daily email newsletter
